Life Science Investing Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Life Science Investing Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
